Clinical review: Molecular mechanisms underlying the role of antithrombin in sepsis

Critical Care

Volumn 10, Issue 1, 2006, Pages

  Wiedermann, Christian J ^a  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; SYNDECAN 4; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BLEEDING; CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOTHELIUM CELL; GRAM NEGATIVE BACTERIUM; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MOLECULAR MECHANICS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; ANIMAL; BLOOD CLOTTING; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTITHROMBIN III; ANTITHROMBINS; BLOOD COAGULATION; HUMANS; SEPSIS;

EID: 34447569555     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc4822     Document Type: Review

References (80)

1. Rosenberg RD Bauer KA Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S Hum Pathol 1987 18 253-262 2950042
2. Hauptman JG Hassouna HI Bell TG Penner JA Emerson TE Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation Circ Shock 1988 25 111-122 3390893
3. Hiller E Pihusch R Thrombophilia caused by congenital disorders of blood coagulation Fortschr Med 1998 116 26-32 9846471
4. Mammen EF The role of antithrombin III in DIC Biol Clin Haematol 1987 Suppl 1 69-73
5. de Jonge E Levi M Stoutenbeek CP van Deventer SJ Current drug treatment strategies for disseminated intravascular coagulation Drugs 1998 55 767-777 10.2165/00003495-199855060-00004 9617592
6. Mammen EF Miyakawa T Phillips TF Assarian GS Brown JM Murano G Human antithrombin concentrates and experimental disseminated intravascular coagulation Semin Thromb Hemost 1985 11 373-383 4071063
7. Levi M Ten Cate H Disseminated intravascular coagulation N Engl J Med 1999 341 586-592 10.1056/NEJM199908193410807 10451465
8. Schregel W Straub H Wolk G Schneider R Successful therapy of consumption coagulopathy in EPH gestosis with multiple organ failure [in German] Anasth Intensivther Not-fallmed 1984 19 201-203
9. Dickneite G Paques EP Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae-induced sepsis Thromb Haemost 1993 69 98-102 8456437
10. Emerson TE Jr Fournel MA Leach WJ Redens TB Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat Circ Shock 1987 21 1-13 3545529
11. Redens TB Leach WJ Bogdanoff DA Emerson TE Jr Synergistic protection from lung damage by combining antithrombin-III and alpha-1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model Circ Shock 1988 26 15-26 3056631
12. Ronneberger H Hein B Effect of antithrombin III on experimental hepatotoxin poisoning in dogs [in German] Arzneimittelforschung 1984 34 277-279 6539607
13. Taylor FB Jr Emerson TE Jr Jordan R Chang AK Blick KE Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons Circ Shock 1988 26 227-235 3061681
14. Baudo F Caimi TM de Cataldo F Ravizza A Arlati S Casella G Carugo D Palareti G Legnani C Ridolfi L Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study Intensive Care Med 1998 24 336-342 10.1007/s001340050576 9609411
15. Eisele B Lamy M Thijs LG Keinecke HO Schuster HP Matthias FR Fourrier F Heinrichs H Delvos U Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis Intensive Care Med 1998 24 663-672 10.1007/s001340050642 9722035
16. Fourrier F Chopin C Huart JJ Runge I Caron C Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation Chest 1993 104 882-888 8365305
17. Inthorn D Hoffmann N Hartl WH Mühlbayer D Jochum M Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis Shock 1998 10 90-96 9721974
18. Vinazzer H Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation Semin Thromb Hemost 1989 15 347-352 2688106
19. Warren BL Eid A Singer P Pillay SS Carl P Novak I Chalupa P Atherstone A Penzes I Kubler A KyberSept Trial Study Group Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial JAMA 2001 286 1869-1878 10.1001/jama.286.15.1869 11597289
20. Abildgaard U Binding of thrombin to antithrombin III Scand J Clin Lab Invest 1969 24 23-27 5374920
21. Schuster HP Eisele B Keinecke HO S-antithrombin III study: Antithrombin III in patients with sepsis Intensive Care Med 1998 Suppl 1 76
22. Turk B Brieditis I Bock SC Olson ST Bjork I The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change Biochemistry 1997 36 6682-6691 10.1021/bi9702492 9184148
23. Andersson LO Engman L Henningsson E Crossed immuno-electrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III-thrombin complex J Immunol Methods 1977 14 271-281 10.1016/0022-1759(77)90138-7 557071
24. Perlmutter DH Glover GI Rivetna M Schasteen CS Fallon RJ Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes Proc Natl Acad Sci USA 1990 87 3753-3757 53981 2160076
25. Pizzo SV Serpin receptor 1: A hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes Am J Med 1989 87 10S-14S 10.1016/0002-9343(89)80524-8 2552799
26. Bombeli T Mueller M Haeberli A Anticoagulant properties of the vascular endothelium Thromb Haemost 1997 77 408-423 9065986
27. Taylor FB Jr Emerson TE Jr Jordan R Chang AK Blick KE Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons Circ Shock 1988 26 227-235 3061681
28. Taylor FB Jr Chang AC Peer GT Mather T Blick K Catlett R Lockhart MS Esmon CT DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage Blood 1991 78 364-368 2070073
29. Yamauchi T Umeda F Inoguchi T Nawata H Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells Biochem Biophys Res Commun 1989 163 1404-1411 10.1016/0006-291X(89)91135-2 2675842
30. Horie S Ishii H Kazama M Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells Thromb Res 1990 59 895-904 10.1016/0049-3848(90)90113-Q 2175954
31. Harada N Okajima K Kushimoto S Isobe H Tanaka K Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin Blood 1999 93 157-164 9864157
32. Uchiba M Okajima K Murakami K Okabe H Takatsuki K Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III Am J Physiol 1996 270 L921-L930 8764216
33. Ostrovsky L Woodman RC Payne D Teoh D Kubes P Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion Circulation 1997 96 2302-2310 9337204
34. Hoffmann JN Vollmar B Inthorn D Schildberg FW Menger MD Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway Am J Physiol Cell Physiol 2000 279 C98-C107 10898721
35. Neviere R Tournoys A Mordon S Marechal X Song FL Jourdain M Fourrier F Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats Shock 2001 15 220-225 11236906
36. Kaneider NC Reinisch CM Dunzendorfer S Romisch J Wieder-mann CJ Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes J Cell Sci 2002 115 227-236 11801740
37. Kaneider NC Egger P Dunzendorfer S Wiedermann CJ Syndecan-4 as antithrombin receptor of human neutrophils Biochem Biophys Res Commun 2001 287 424-426 10.1006/bbrc.2001.5534
38. Dunzendorfer S Kaneider N Rabensteiner A Meierhofer C Reinisch C Romisch J Wiedermann CJ Cell-surface heparan sulfate proteoglycan-mediated regulation of human neu-trophil migration by the serpin antithrombin III Blood 2001 97 1079-1085 10.1182/blood.V97.4.1079 11159540
39. Mizutani A Okajima K Uchiba M Isobe H Harada N Mizutani S Noguchi T Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production Blood 2003 101 3029-3036 10.1182/blood-2002-08-2406 12480701
40. Harada N Okajima K Uchiba M Kushimoto S Isobe H Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-1 Thromb Haemost 2004 92 550-558 15351851
41. Hirose K Okajima K Uchiba M Nakano KY Utoh J Kitamura N Antithrombin reduces the ischemia/reperfusion-induced spinal cord injury in rats by attenuating inflammatory responses Thromb Haemost 2004 91 162-170 14691582
42. Taoka Y Okajima K Uchiba M Antithrombin reduces compression-induced spinal cord injury in rats J Neurotrauma 2004 21 1818-1830 10.1089/ neu.2004.21.1818 15684771
43. Feistritzer C Kaneider NC Sturn DH Wiedermann CJ Syndecan-4-dependent migration of human eosinophils Clin Exp Allergy 2004 34 696-703 10.1111/ j.1365-2222.2004.1853.x 15144459
44. Olson ST Bjork I Sheffer R Craig PA Shore JD Choay J Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement J Biol Chem 1992 267 12528-12538 1618758
45. Ishiguro K Kojima T Muramatsu T Syndecan-4 as a molecule involved in defense mechanisms Glycoconj J 2002 19 315-318 10.1023/A:1025308702966 12975610
46. Hoffmann JN Vollmar B Laschke MW Inthorn D Kaneider NC Dunzendorfer S Wiedermann CJ Romisch J Schildberg FW Menger MD Adverse effect of heparin on antithrombin action during endotoxemia: Microhemodynamic and cellular mechanisms Thromb Haemost 2002 88 242-252 12195696
47. Kaneider NC Forster E Mosheimer B Sturn DH Wiedermann CJ Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin Thromb Haemost 2003 90 1150-1157 14652650
48. Oelschlager C Romisch J Staubitz A Stauss H Leithauser B Tillmanns H Holschermann H Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells Blood 2002 99 4015-4020 10.1182/blood.V99.11.4015 12010802
49. Mansell A Reinicke A Worrall DM O'Neill LA The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-kappaB activation by TLR-4 FEBS Lett 2001 508 313-317 10.1016/S0014-5793(01)03077-0 11728442
50. Hatada EN Krappmann D Scheidereit C NF-kappaB and the innate immune response Curr Opin Immunol 2000 12 52-58 10.1016/S0952-7915(99)00050-3 10679399
51. Minnema MC Chang AC Jansen PM Lubbers YT Pratt BM Whittaker BG Taylor FB Hack CE Friedman B Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli Blood 2000 95 1117-1123 10666179
52. Souter PJ Thomas S Hubbard AR Poole S Romisch J Gray E Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood Crit Care Med 2001 29 134-139 10.1097/ 00003246-200101000-00027 11176173
53. Gritti D Malinverno A Gasparetto C Wiedermann CJ Ricevuti R Attenuation of leukocyte beta 2-integrin expression by antithrombin-III Int J Immunopathol Pharmacol 2004 17 27-32 15000863
54. Uchiba M Okajima K Kaun C Wojta J Binder BR Inhibition of the endothelial cell activation by antithrombin in vitro Thromb Haemost 2004 92 1420-1427 15583752
55. Harada N Okajima K Yuksel M Isobe H Contribution of capsaicin-sensitive sensory neurons to antithrombin-induced reduction of ischemia/ reperfusion-induced liver injury in rats Thromb Haemost 2005 93 48-56 15630490
56. Spannagl M Hoffmann H Siebeck M Weipert J Schwarz HP Schramm W A purified antithrombin III-heparin complex as a potent inhibitor of thrombin in porcine endotoxin shock Thromb Res 1991 61 1-10 10.1016/ 0049-3848(91)90163-Q 2020936
57. Hoffmann J Wiedermann CJ Juers M Ostermann H Kienast J Briegel J Strauss R Warren BL Opal SM Benefit/risk profile of high-dose antithrombin III in the treatment of severe sepsis without concomitant heparin Thromb Haemost 2006
58. Opal SM Kessler CM Roemisch J Knaub S Antithrombin, heparin, and heparan sulfate Crit Care Med 2002 Suppl S325-S331 10.1097/ 00003246-200205001-00024
59. Corrigan JJ Jordan CM Heparin therapy in septicemia with disseminated intravascular coagulation N Engl J Med 1970 283 778-782 4989565
60. Sleight P Debate: Subgroup analyFes in clinical trials: fun to look at but don't believe them! Curr Control Trials Cardiovasc Med 2000 1 25-27 59592 11714402 10.1186/CVM-1-1-025
61. Wiedermann CJ Hoffmann JN Juers M Ostermann H Kienast J Briegel J Strauss R Keinecke HO Warren BL Opal SM for the KyberSept investigators High-dose antithrombin III in the treatment of severe sepsis with a high risk of death: Efficacy and safety Crit Care Med 2006 34 285-292 10.1097/ 01.CCM.0000194731.08896.99 16424704
62. van Deventer SJ Buller HR ten Cate JW Aarden LA Hack CE Sturk A Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways Blood 1990 76 2520-2526 2124934
63. van der Poll T Buller HR ten Cate H Wortel CH Bauer KA van Deventer SJ Hack CE Sauerwein HP Rosenberg RD ten Cate JW Activation of coagulation after administration of tumor necrosis factor to normal subjects N Engl J Med 1990 322 1622-1627 2188129
64. Levi M ten Cate H Bauer KA van der Poll T Edgington TS Buller HR van Deventer SJ Hack CE ten Cate JW Rosenberg RD Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees J Clin Invest 1994 93 114-120 293743 8282778
65. Drake TA Cheng J Chang A Taylor FB Jr Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis Am J Pathol 1993 142 1458-1470 7684196
66. Nawroth PP Stern DM Modulation of endothelial cell hemostatic properties by tumor necrosis factor J Exp Med 1986 163 740-745 10.1084/ jem.163.3.740 3753996
67. Osterud B Flaegstad T Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavourable prognosis Thromb Haemost 1983 49 5-7 6845273
68. Martinez MA Pena JM Fernandez A Jimenez M Juarez S Madero R Vazquez JJ Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha Crit Care Med 1999 27 1303-1308 10.1097/00003246-199907000-00017 10446824
69. Feistritzer C Mosheimer BA Tancevski I Kaneider NC Sturn DH Patsch JR Wiedermann CJ Src tyrosine kinase-dependent migratory effects of antithrombin in leukocytes Exp Cell Res 2005 305 214-220 10.1016/ j.yexcr.2005.01.001 15777801
70. Simons M Horowitz A Syndecan-4-mediated signalling Cell Signal 2001 13 855-862 10.1016/S0898-6568(01)00190-5 11728825
71. Kaneider NC Feistritzer C Gritti D Mosheimer BA Ricevuti G Patsch JR Wiedermann CJ Expression and function of syndecan-4 in human platelets Thromb Haemost 2005 93 1120-1127 15968398
72. Kienast J Juers M Wiedermann CJ Hoffmann JN Ostermann H Briegel J Strauss R Warren BL Opal SM Treatment effects of high-dose antithrombin III without concomitant heparin in patients with severe sepsis with and without disseminated intravascular coagulation J Thromb Haemost 2006 4 90-97 10.1111/j.1538-7836.2005.01697.x 16409457
73. Kipnis E Guery BP Tournoys A Leroy X Robriquet L Fialdes P Neviere R Fourrier F Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury Shock 2004 21 444-451 10.1097/ 00024382-200405000-00008 15087821
74. Di Micco B Di Micco P Lepretti M Stiuso P Donnarumma G Iovene MR Capasso R Tufano MA Hyperproduction of fibrin and inefficacy of antithrombin III and α2 macroglobulin in the presence of bacterial porins Int J Exp Pathol 2005 86 241-245 10.1111/j.0959-9673.2005.00430.x 16045546
75. Edwards AM Jenkinson HF Woodward MJ Dymock D Binding properties and adhesion-mediating regions of the major sheath protein of Treponema denticola ATCC 35405 Infect Immun 2005 73 2891-2898 1087326 15845495 10.1128/IAI.73.5.2891-2898.2005
76. Masson D Tschopp J Inhibition of lymphocyte protease granzyme A by antithrombin III Mol Immunol 1988 25 1283-1289 10.1016/ 0161-5890(88)90043-0 3266293
77. Zeerleder S Hack CE Caliezi C van Mierlo G Eerenberg-Belmer A Wolbink A Wuillenmin WA Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction Clin Immunol 2005 116 158-165 10.1016/j.clim.2005.03.006 15993363
78. Wiedermann CJ Kaneider NC Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis Ann Med 2004 36 194-203 10.1080/07853890410027943 15181975
79. Kountchev J Bijuklic K Bellmann R Wiedermann CJ Joannidis M Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis Crit Care 2005 9 R596-R600 10.1186/cc3808 16280058
80. Levi M Antithrombin in sepsis revisited Crit Care 2005 9 624-625 16356248